Anthera Pharmaceuticals (NASDAQ:ANTH) was upgraded by ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued to investors on Sunday.

Other analysts have also recently issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of Anthera Pharmaceuticals in a research report on Tuesday, September 19th. Zacks Investment Research upgraded shares of Anthera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.00 price objective on the stock in a report on Tuesday, October 10th.

Shares of Anthera Pharmaceuticals (ANTH) traded up $0.06 during trading on Friday, reaching $1.65. 353,518 shares of the company were exchanged, compared to its average volume of 304,761. Anthera Pharmaceuticals has a 12-month low of $1.20 and a 12-month high of $6.24. The stock has a market cap of $22.85, a PE ratio of -0.30 and a beta of 2.71.

Anthera Pharmaceuticals (NASDAQ:ANTH) last announced its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.32. During the same quarter in the previous year, the firm earned ($4.85) EPS. analysts predict that Anthera Pharmaceuticals will post -3.09 EPS for the current year.

A hedge fund recently raised its stake in Anthera Pharmaceuticals stock. Wedbush Securities Inc. boosted its position in Anthera Pharmaceuticals Inc (NASDAQ:ANTH) by 75.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 73,764 shares of the biopharmaceutical company’s stock after buying an additional 31,800 shares during the quarter. Wedbush Securities Inc. owned 0.68% of Anthera Pharmaceuticals worth $106,000 at the end of the most recent quarter. 16.10% of the stock is currently owned by institutional investors and hedge funds.

WARNING: This piece was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Receive News & Stock Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related stocks with our FREE daily email newsletter.